management, non-small cell lung cancer, staging.The treatment of non-small cell lung cancer (NSCLC) depends on staging based on tumour (T), nodal (N) and metastasis (M) descriptors. Stages I and II tumours are potentially curable with surgery alone. Stage IIIA T3 tumours are also ...
small-cell lung cancer.Advanced non–small-cell lung cancer (NSCLC) remains an incurable disease despite significant progress in chemotherapy. We conducted a phase II clinical trial to investigate the efficacy and toxicity of a cisplatin, etoposide, and 5-fluorouracil (5-FU) combination in advanced...
Hawkins N, Scott DA, Woods BS, Thatcher, N. No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value Health 2009;12: 996 -1003.Hawkins N, Scott DA, Thatcher N. 2010. Response to comments on "No ...
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies...
High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure–response relationship...
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Targeted therapy against the epidermal growth factor receptor (EGFR) is a promising treatment approach for NSCLC. However, resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major challenge in it...